Seoul Pharma Co., Ltd (KOSDAQ:018680)

Seoul Pharma Statistics

Total Valuation

Seoul Pharma has a market cap or net worth of KRW 26.12 billion. The enterprise value is 25.21 billion.

Market Cap	26.12B
Enterprise Value	25.21B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Seoul Pharma has 11.66 million shares outstanding.

Current Share Class	11.66M
Shares Outstanding	11.66M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.07%
Owned by Institutions (%)	n/a
Float	4.72M

Valuation Ratios

The trailing PE ratio is 35.98.

PE Ratio	35.98
Forward PE	n/a
PS Ratio	0.51
PB Ratio	0.64
P/TBV Ratio	0.65
P/FCF Ratio	2.60
P/OCF Ratio	2.38
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.20, with an EV/FCF ratio of 2.51.

EV / Earnings	34.73
EV / Sales	0.49
EV / EBITDA	19.20
EV / EBIT	n/a
EV / FCF	2.51

Financial Position

The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.42.

Current Ratio	2.38
Quick Ratio	1.59
Debt / Equity	0.42
Debt / EBITDA	13.12
Debt / FCF	1.72
Interest Coverage	-2.34

Financial Efficiency

Return on equity (ROE) is 1.80% and return on invested capital (ROIC) is -3.05%.

Return on Equity (ROE)	1.80%
Return on Assets (ROA)	-1.19%
Return on Invested Capital (ROIC)	-3.05%
Return on Capital Employed (ROCE)	-2.38%
Weighted Average Cost of Capital (WACC)	5.02%
Revenue Per Employee	298.41M
Profits Per Employee	4.22M
Employee Count	172
Asset Turnover	0.72
Inventory Turnover	1.73

Taxes

Income Tax	-49.60M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -32.35% in the last 52 weeks. The beta is 0.42, so Seoul Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.42
52-Week Price Change	-32.35%
50-Day Moving Average	2,710.40
200-Day Moving Average	2,972.60
Relative Strength Index (RSI)	15.18
Average Volume (20 Days)	9,084

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Seoul Pharma had revenue of KRW 51.33 billion and earned 725.89 million in profits.

Revenue	51.33B
Gross Profit	30.89B
Operating Income	-1.35B
Pretax Income	676.29M
Net Income	725.89M
EBITDA	1.31B
EBIT	-1.35B
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 18.13 billion in cash and 17.22 billion in debt, with a net cash position of 903.78 million or 77.52 per share.

Cash & Cash Equivalents	18.13B
Total Debt	17.22B
Net Cash	903.78M
Net Cash Per Share	77.52
Equity (Book Value)	40.86B
Book Value Per Share	n/a
Working Capital	19.48B

Cash Flow

In the last 12 months, operating cash flow was 10.95 billion and capital expenditures -910.37 million, giving a free cash flow of 10.04 billion.

Operating Cash Flow	10.95B
Capital Expenditures	-910.37M
Depreciation & Amortization	2.66B
Net Borrowing	1.37B
Free Cash Flow	10.04B
FCF Per Share	861.30

Margins

Gross margin is 60.18%, with operating and profit margins of -2.63% and 1.41%.

Gross Margin	60.18%
Operating Margin	-2.63%
Pretax Margin	1.32%
Profit Margin	1.41%
EBITDA Margin	2.56%
EBIT Margin	-2.63%
FCF Margin	19.57%

Dividends & Yields

Seoul Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	2.78%
FCF Yield	38.45%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on April 12, 2004. It was a forward split with a ratio of 2.

Last Split Date	Apr 12, 2004
Split Type	Forward
Split Ratio	2

Scores

Seoul Pharma has an Altman Z-Score of 1.84 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.84
Piotroski F-Score	4